First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors
GDF15 is upregulated in the tumor microenvironment and suppresses antitumor immune responses. In this first-in-human trial, the anti-GDF15 antibody AZD8853 was well tolerated in previously treated patients with advanced/metastatic solid tumors, but no objective responses or PD effects were seen and GDF15 suppression was not sustained.
Authors
- Elhan Sanai
- John Hood (ORCID: https://orcid.org/0009-0007-9752-065X)
- Michael Pluta
- Olumide B. Gbolahan (ORCID: https://orcid.org/0000-0002-0598-4809)
- Albiruni R. Abdul Razak (ORCID: https://orcid.org/0000-0001-7657-9950)
- Patricia LoRusso (ORCID: https://orcid.org/0000-0001-7144-036X)
- Benedito A. Carneiro (ORCID: https://orcid.org/0000-0002-5468-1126)
- Duncan Ian Jodrell (ORCID: https://orcid.org/0000-0001-9360-1670)
- Arthur W. Lambert (ORCID: https://orcid.org/0000-0002-2989-7961)
- Véronique Bragulat
- Rakesh Kumar
- John Hilton (ORCID: https://orcid.org/0000-0002-6280-8633)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Emory University (US)
- University of Cambridge (GB)
- Brown University (US)
- Ottawa Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- Yale Cancer Center (US)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0565
- Citations
- 4
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.67
Funders
- AstraZeneca
- Eisai